Published in Med Care on May 01, 2012
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst (2013) 0.98
Offering prenatal diagnostic tests: European guidelines for clinical practice [corrected]. Eur J Hum Genet (2013) 0.95
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. J Comp Eff Res (2012) 0.84
Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach. J Comp Eff Res (2012) 0.83
Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research. Genet Med (2012) 0.78
Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med (2017) 0.77
Household Air Pollution and CVD: Identifying Best Directions for Research. Glob Heart (2012) 0.75
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet (2009) 8.73
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood (2006) 7.63
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol (2007) 3.88
BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68
Pragmatic clinical trials. Complement Ther Med (2004) 3.47
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.80
Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics (2006) 2.59
How best to engage patients, doctors, and other stakeholders in designing comparative effectiveness studies. Health Aff (Millwood) (2010) 1.67
Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. J Health Econ (2001) 1.51
Horizon scanning for new genomic tests. Genet Med (2011) 1.36
Ca 15-3 in the follow-up of localised breast cancer: a prospective study. Eur J Cancer (2002) 1.24
Focusing technology assessment using medical decision theory. Med Decis Making (1988) 1.22
Economic evaluation alongside pragmatic randomised trials: developing a standard operating procedure for clinical trials units. Trials (2008) 1.13
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol (1997) 1.01
The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther (2009) 0.96
Medical technology horizon scanning. Australas Phys Eng Sci Med (2005) 0.84
Priority setting for horizon scanning of new health technologies in Denmark: views of health care stakeholders and health economists. Health Policy (2005) 0.83
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med (2003) 7.28
The case for early detection. Nat Rev Cancer (2003) 6.96
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol (2007) 3.79
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol (2009) 3.72
Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis (2005) 3.28
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2011) 2.46
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med (2002) 2.43
Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer (2003) 2.23
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr (2006) 2.15
Chordoma: the nonsarcoma primary bone tumor. Oncologist (2007) 2.10
Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med (2010) 2.04
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol (2010) 1.84
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res (2003) 1.81
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost (2008) 1.76
Vaccination of chickens against H5N1 avian influenza in the face of an outbreak interrupts virus transmission. Avian Pathol (2004) 1.72
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol (2004) 1.69
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
Medical and pediatric oncology, not adult and pediatric oncology. J Clin Oncol (2005) 1.66
Pulmonary nodule volumetric measurement variability as a function of CT slice thickness and nodule morphology. AJR Am J Roentgenol (2007) 1.65
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med (2012) 1.58
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genet Med (2012) 1.52
Ultrasonographic evaluation of melamine-exposed children in Hong Kong. N Engl J Med (2009) 1.52
In regard to the radiotherapy of myxopapillary ependymomas. Int J Radiat Oncol Biol Phys (2002) 1.48
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg (2004) 1.45
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics (2006) 1.44
Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr (2009) 1.43
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Neonates investigated for influenza-like illness during the outbreak of pandemic H1N1 2009: trivial infections but major triage implications. Indian J Pediatr (2010) 1.38
Increased nocturnal blood pressure in healthy prepubertal twins. J Hypertens (2003) 1.38
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol (2009) 1.38
Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res (2004) 1.35
Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. Oncologist (2008) 1.34
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer (2013) 1.32
Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinformatics (2010) 1.32
Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genet Med (2012) 1.32
Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch Gen Psychiatry (2005) 1.30
Selection of response criteria for clinical trials of sarcoma treatment. Oncologist (2008) 1.30
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat (2005) 1.30
Renal screening in children after exposure to low dose melamine in Hong Kong: cross sectional study. BMJ (2008) 1.30
Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci (2012) 1.30
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Uromodulin mutations causing familial juvenile hyperuricaemic nephropathy lead to protein maturation defects and retention in the endoplasmic reticulum. Hum Mol Genet (2009) 1.24
A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health (2011) 1.24
Cancer biomarkers: a systems approach. Nat Biotechnol (2006) 1.23
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res (2010) 1.23
Evaluation of a cervical cancer control intervention using lay health workers for Vietnamese American women. Am J Public Health (2010) 1.20
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med (2004) 1.19
A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. J Am Coll Surg (2003) 1.18
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol (2005) 1.16
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control (2012) 1.15
Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer (2011) 1.14
Estimating the costs of induced abortion in Uganda: a model-based analysis. BMC Public Health (2011) 1.13
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med (2003) 1.12
The development and testing of a measure assessing clinician beliefs about patient self-management. Health Expect (2009) 1.12
The de novo cytosine methyltransferase DRM2 requires intact UBA domains and a catalytically mutated paralog DRM3 during RNA-directed DNA methylation in Arabidopsis thaliana. PLoS Genet (2010) 1.12
How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. Health Aff (Millwood) (2011) 1.11
Economic analyses of human genetics services: a systematic review. Genet Med (2005) 1.10
Impact of global economic disparities on practices and outcomes of chronic peritoneal dialysis in children: insights from the International Pediatric Peritoneal Dialysis Network Registry. Perit Dial Int (2012) 1.10
Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation (2003) 1.09
Relation between reaction time and reach errors during visuomotor adaptation. Behav Brain Res (2010) 1.09
The public health response to epidemic syphilis, San Francisco, 1999-2004. Sex Transm Dis (2005) 1.08
Examining the cost-effectiveness of cancer screening promotion. Cancer (2004) 1.07
The burden of kidney disease in indigenous children of Australia and New Zealand, epidemiology, antecedent factors and progression to chronic kidney disease. J Paediatr Child Health (2010) 1.07
Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc (2003) 1.07
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA (2013) 1.07
A review of selected patient-generated outcome measures and their application in clinical trials. Value Health (2003) 1.07
Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys (2007) 1.07
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer (2008) 1.06
AACR Cancer Progress Report 2014. Clin Cancer Res (2014) 1.05
Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer (2006) 1.04